Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD2-H82E8 | Human | Biotinylated Human CD52 Protein, His,Avitag™ |  |
|
|
| CD2-H525a | Human | Human CD52 Protein, Fc Tag |  |
|
|
| CD2-H82F3 | Human | Biotinylated Human CD52 Protein, Fc,Avitag™ |  |
|
Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | LDP-03; GZ-402673 | Approved | Genzyme Corp, Bayer AG | Campath, Lemtrada, MabCampath | Japan | Leukemia, Lymphocytic, Chronic, B-Cell | Sanofi | 2001-05-07 | Myositis, Inclusion Body; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Sezary Syndrome; Lymphoproliferative Disorders; Peritoneal Neoplasms; Pancytopenia; Diabetes Mellitus, Type 1; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; Leukemia-Lymphoma, Adult T-Cell; Kidney Diseases; Graft vs Host Disease; Ovarian Neoplasms; Bone marrow transplant rejection; Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Multiple Sclerosis, Relapsing-Remitting; Rejection of renal transplantation; Leukemia | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Multiple Sclerosis; Leukemia, B-Cell | Details |
| Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details | |
| ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular | Details |
This web search service is supported by Google Inc.
A-Z
